Virginia G. Kaklamani, MD, DSc, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen ...

Brexucabtagene autoleucel showed comparable efficacy outcomes in patients aged 60 to 69 with relapsed/refractory B-cell acute ...

Imlunestrant, a next-generation SERD, improves progression-free survival in ER-positive advanced breast cancer patients ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced ...

Pfizer's PATINA trial highlights IBRANCE's potential in HR+/HER2+ metastatic breast cancer, improving outcomes with a ...

A HER2-positive status reflects breast cancer cells with extra copies of the HER2 gene, or higher expression of HER2 proteins ...

Real-world study compares the efficacy and safety of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), ...

Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence supporting the CDK4/6 inhibitor class’ use in patients with a specific type of ...

Researchers sought to determine whether CAR-T therapy would be safe and effective in patients with CLL and Richter transformation.

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first ...

Adding pyrotinib to trastuzumab and docetaxel prolonged progression-free survival in patients with HER2-positive metastatic breast cancer.

Eli Lilly LLY announced results from the phase III EMBER-3 study, which showed that treatment with its orally administered ...